jbm healthcare (02161.HK) announced a joyful profit, expecting the attributable comprehensive profit for the six months ending September this year to increase by not less than 50% compared to last year.

The group mentioned that the substantial increase in comprehensive profit is mainly attributed to the strong sales momentum of the group's core brands, especially Hejigong in the branded medicine division and Baojiwan in the traditional chinese medicine division. In addition, the continued growth of the group's concentrated traditional chinese medicine granule business also provides further support.